After having been twice rejected by the FDA, Sprout Pharmaceuticals Inc.’s Addyi (pronounced add-ee), touted as “female Viagra” has finally received the regulatory agency’s thumbs up to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women, which is the most common form of female sexual dysfunction.